Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Chronic Heart Failure Guidelines

05.09.2005


Chronic heart failure (CHF) is common, deadly, disabling, costly but fortunately - treatable. During the last ten to 15 years, treatment of CHF has been dramatically improved by pharmacological therapy and devices. Treatment also has become more complicated. The Guidelines are intended as a support for practising physicians and other health care professionals as most patients with CHF are treated by non-cardiologists. Heart failure clinics are common in Scandinavia with specialized nurses managing patients.



Diagnosis

Symptoms and signs are essential for the diagnosis as they alert the observer to the possibility that heart failure exists. The clinical suspicion of heart failure must be confirmed by more objective tests particularly aimed at assessing cardiac function.


Treatment

Treatment of CHF is aimed at prolonging life and reducing morbidity and symptoms. Quality of life in patients with CHF is reduced as exemplified by frequent hospitalisations when symptoms increase. Hospitalisations for heart failure are costly and reductions are important.

Therapy should include a combination of agents counteracting the adrenergic and renin-angiotensin systems. New neurohormonal antagonists, ACE-inhibitors and beta-blockers together with diuretics make the platform for therapy.

The most recent pharmacologic experience demonstrates the value of ARBs not only as an alternative to ACE-inhibitors but also in addition to these important agents both in CHF as well as in heart failure after MI. The role of aldosterone antagonists has expanded to left ventricular dysfunction after a myocardial infarction.

The role of device therapy (biventricular pacing and ICDs) on top of optimal pharmacological therapy has been markedly expanded during the last year with new trials clarifying the possibilities with these products.

Conclusion

Treatment of CHF has advanced further with more options providing additional life-saving therapies beyond and above ACE-inhibitors and beta-blockers.

Gina Dellios | alfa
Further information:
http://www.escardio.org/vpo/ESC_congress_information/ConferenceReleases/

More articles from Health and Medicine:

nachricht PET imaging tracks Zika virus infection, disease progression in mouse model
20.09.2017 | US Army Medical Research Institute of Infectious Diseases

nachricht 'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Molecular Force Sensors

20.09.2017 | Life Sciences

Producing electricity during flight

20.09.2017 | Power and Electrical Engineering

Tiny lasers from a gallery of whispers

20.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>